ID FAAH1_RAT Reviewed; 579 AA. AC P97612; Q5BKA3; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1997, sequence version 1. DT 24-JAN-2024, entry version 170. DE RecName: Full=Fatty-acid amide hydrolase 1; DE EC=3.5.1.99 {ECO:0000269|PubMed:10526230, ECO:0000269|PubMed:11128635, ECO:0000269|PubMed:17649977, ECO:0000269|PubMed:9122178, ECO:0000269|PubMed:9299394, ECO:0000269|PubMed:9790682}; DE AltName: Full=Anandamide amidase; DE AltName: Full=Anandamide amidohydrolase 1; DE AltName: Full=Fatty acid ester hydrolase; DE EC=3.1.1.- {ECO:0000269|PubMed:10526230, ECO:0000269|PubMed:15533037, ECO:0000269|PubMed:17649977}; DE AltName: Full=Oleamide hydrolase 1; GN Name=Faah; Synonyms=Faah1; OS Rattus norvegicus (Rat). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; OC Murinae; Rattus. OX NCBI_TaxID=10116; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE. RC TISSUE=Liver; RX PubMed=8900284; DOI=10.1038/384083a0; RA Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., RA Gilula N.B.; RT "Molecular characterization of an enzyme that degrades neuromodulatory RT fatty-acid amides."; RL Nature 384:83-87(1996). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND SUBCELLULAR RP LOCATION. RX PubMed=9122178; DOI=10.1073/pnas.94.6.2238; RA Giang D.K., Cravatt B.F.; RT "Molecular characterization of human and mouse fatty acid amide RT hydrolases."; RL Proc. Natl. Acad. Sci. U.S.A. 94:2238-2242(1997). RN [4] RP TISSUE SPECIFICITY. RX PubMed=9452020; RX DOI=10.1002/(sici)1097-4547(19971215)50:6<1047::aid-jnr16>3.0.co;2-1; RA Thomas E.A., Cravatt B.F., Danielson P.E., Gilula N.B., Sutcliffe J.G.; RT "Fatty acid amide hydrolase, the degradative enzyme for anandamide and RT oleamide, has selective distribution in neurons within the rat central RT nervous system."; RL J. Neurosci. Res. 50:1047-1052(1997). RN [5] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=9299394; DOI=10.1006/bbrc.1997.7180; RA Kurahashi Y., Ueda N., Suzuki H., Suzuki M., Yamamoto S.; RT "Reversible hydrolysis and synthesis of anandamide demonstrated by RT recombinant rat fatty-acid amide hydrolase."; RL Biochem. Biophys. Res. Commun. 237:512-515(1997). RN [6] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND RP SUBCELLULAR LOCATION. RX PubMed=9790682; DOI=10.1021/bi981733n; RA Patricelli M.P., Lashuel H.A., Giang D.K., Kelly J.W., Cravatt B.F.; RT "Comparative characterization of a wild type and transmembrane domain- RT deleted fatty acid amide hydrolase: identification of the transmembrane RT domain as a site for oligomerization."; RL Biochemistry 37:15177-15187(1998). RN [7] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=10526230; DOI=10.1016/s1388-1981(99)00143-2; RA Goparaju S.K., Kurahashi Y., Suzuki H., Ueda N., Yamamoto S.; RT "Anandamide amidohydrolase of porcine brain: cDNA cloning, functional RT expression and site-directed mutagenesis."; RL Biochim. Biophys. Acta 1441:77-84(1999). RN [8] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=11128635; DOI=10.1016/s0960-894x(00)00528-x; RA Boger D.L., Fecik R.A., Patterson J.E., Miyauchi H., Patricelli M.P., RA Cravatt B.F.; RT "Fatty acid amide hydrolase substrate specificity."; RL Bioorg. Med. Chem. Lett. 10:2613-2616(2000). RN [9] RP CHARACTERIZATION, AND MUTAGENESIS OF LYS-142 AND SER-217. RX PubMed=12734197; DOI=10.1074/jbc.m303922200; RA McKinney M.K., Cravatt B.F.; RT "Evidence for distinct roles in catalysis for residues of the serine- RT serine-lysine catalytic triad of fatty acid amide hydrolase."; RL J. Biol. Chem. 278:37393-37399(2003). RN [10] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15533037; DOI=10.1021/bi0480335; RA Saghatelian A., Trauger S.A., Want E.J., Hawkins E.G., Siuzdak G., RA Cravatt B.F.; RT "Assignment of endogenous substrates to enzymes by global metabolite RT profiling."; RL Biochemistry 43:14332-14339(2004). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=17649977; DOI=10.1021/bi7005898; RA Vila A., Rosengarth A., Piomelli D., Cravatt B., Marnett L.J.; RT "Hydrolysis of prostaglandin glycerol esters by the endocannabinoid- RT hydrolyzing enzymes, monoacylglycerol lipase and fatty acid amide RT hydrolase."; RL Biochemistry 46:9578-9585(2007). RN [12] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 37-573 IN COMPLEX WITH INHIBITOR RP METHOXY-ARACHIDONYL FLUOROPHOSPHATE, SUBUNIT, AND TOPOLOGY. RX PubMed=12459591; DOI=10.1126/science.1076535; RA Bracey M.H., Hanson M.A., Masuda K.R., Stevens R.C., Cravatt B.F.; RT "Structural adaptations in a membrane enzyme that terminates RT endocannabinoid signaling."; RL Science 298:1793-1796(2002). RN [13] RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 32-579 IN COMPLEX WITH INHIBITOR RP PF-750, TOPOLOGY, AND SUBUNIT. RX PubMed=18753625; DOI=10.1073/pnas.0806121105; RA Mileni M., Johnson D.S., Wang Z., Everdeen D.S., Liimatta M., Pabst B., RA Bhattacharya K., Nugent R.A., Kamtekar S., Cravatt B.F., Ahn K., RA Stevens R.C.; RT "Structure-guided inhibitor design for human FAAH by interspecies active RT site conversion."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12820-12824(2008). CC -!- FUNCTION: Catalyzes the hydrolysis of endogenous amidated lipids like CC the sleep-inducing lipid oleamide ((9Z)-octadecenamide), the CC endocannabinoid anandamide (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)- CC ethanolamine), as well as other fatty amides, to their corresponding CC fatty acids, thereby regulating the signaling functions of these CC molecules (PubMed:9122178, PubMed:9299394, PubMed:9790682, CC PubMed:10526230, PubMed:11128635, PubMed:15533037, PubMed:17649977). CC Hydrolyzes polyunsaturated substrate anandamide preferentially as CC compared to monounsaturated substrates (PubMed:9122178, CC PubMed:11128635). It can also catalyze the hydrolysis of the CC endocannabinoid 2-arachidonoylglycerol (2-(5Z,8Z,11Z,14Z- CC eicosatetraenoyl)-glycerol) (PubMed:10526230, PubMed:15533037, CC PubMed:17649977). FAAH cooperates with PM20D1 in the hydrolysis of CC amino acid-conjugated fatty acids such as N-fatty acyl glycine and N- CC fatty acyl-L-serine, thereby acting as a physiological regulator of CC specific subsets of intracellular, but not of extracellular, N-fatty CC acyl amino acids (By similarity). {ECO:0000250|UniProtKB:O08914, CC ECO:0000269|PubMed:10526230, ECO:0000269|PubMed:11128635, CC ECO:0000269|PubMed:15533037, ECO:0000269|PubMed:17649977, CC ECO:0000269|PubMed:9122178, ECO:0000269|PubMed:9299394, CC ECO:0000269|PubMed:9790682}. CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine = CC (5Z,8Z,11Z,14Z)-eicosatetraenoate + ethanolamine; CC Xref=Rhea:RHEA:26136, ChEBI:CHEBI:2700, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:32395, ChEBI:CHEBI:57603; EC=3.5.1.99; CC Evidence={ECO:0000269|PubMed:10526230, ECO:0000269|PubMed:11128635, CC ECO:0000269|PubMed:17649977, ECO:0000269|PubMed:9122178, CC ECO:0000269|PubMed:9299394}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:26137; CC Evidence={ECO:0000269|PubMed:10526230, ECO:0000269|PubMed:11128635, CC ECO:0000269|PubMed:17649977, ECO:0000269|PubMed:9122178, CC ECO:0000269|PubMed:9299394}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(9Z)-octadecenamide + H2O = (9Z)-octadecenoate + NH4(+); CC Xref=Rhea:RHEA:26506, ChEBI:CHEBI:15377, ChEBI:CHEBI:28938, CC ChEBI:CHEBI:30823, ChEBI:CHEBI:116314; EC=3.5.1.99; CC Evidence={ECO:0000269|PubMed:10526230, ECO:0000269|PubMed:11128635, CC ECO:0000269|PubMed:9122178, ECO:0000269|PubMed:9299394, CC ECO:0000269|PubMed:9790682}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:26507; CC Evidence={ECO:0000269|PubMed:10526230, ECO:0000269|PubMed:11128635, CC ECO:0000269|PubMed:9122178, ECO:0000269|PubMed:9299394, CC ECO:0000269|PubMed:9790682}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycerol + H2O = CC (5Z,8Z,11Z,14Z)-eicosatetraenoate + glycerol + H(+); CC Xref=Rhea:RHEA:26132, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:17754, ChEBI:CHEBI:32395, ChEBI:CHEBI:52392; CC Evidence={ECO:0000269|PubMed:10526230, ECO:0000269|PubMed:15533037, CC ECO:0000269|PubMed:17649977}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:26133; CC Evidence={ECO:0000269|PubMed:10526230, ECO:0000269|PubMed:15533037, CC ECO:0000269|PubMed:17649977}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(9Z,12Z,15Z)-octadecatrienamide + H2O = (9Z,12Z,15Z)- CC octadecatrienoate + NH4(+); Xref=Rhea:RHEA:62976, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:28938, ChEBI:CHEBI:32387, ChEBI:CHEBI:142684; CC Evidence={ECO:0000269|PubMed:11128635}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62977; CC Evidence={ECO:0000269|PubMed:11128635}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenamide + H2O = (5Z,8Z,11Z,14Z)- CC eicosatetraenoate + NH4(+); Xref=Rhea:RHEA:63016, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:28938, ChEBI:CHEBI:32395, ChEBI:CHEBI:137830; CC Evidence={ECO:0000269|PubMed:11128635, ECO:0000269|PubMed:9299394}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63017; CC Evidence={ECO:0000269|PubMed:11128635, ECO:0000269|PubMed:9299394}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(6Z)-octadecenamide + H2O = (6Z)-octadecenoate + NH4(+); CC Xref=Rhea:RHEA:63008, ChEBI:CHEBI:15377, ChEBI:CHEBI:28938, CC ChEBI:CHEBI:32375, ChEBI:CHEBI:146168; CC Evidence={ECO:0000269|PubMed:11128635}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63009; CC Evidence={ECO:0000269|PubMed:11128635}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(15Z)-tetracosenamide + H2O = (15Z)-tetracosenoate + NH4(+); CC Xref=Rhea:RHEA:63028, ChEBI:CHEBI:15377, ChEBI:CHEBI:28938, CC ChEBI:CHEBI:32392, ChEBI:CHEBI:146166; CC Evidence={ECO:0000269|PubMed:11128635}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63029; CC Evidence={ECO:0000269|PubMed:11128635}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(8Z,11Z,14Z)-eicosatrienamide + H2O = (8Z,11Z,14Z)- CC eicosatrienoate + NH4(+); Xref=Rhea:RHEA:62996, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:28938, ChEBI:CHEBI:71589, ChEBI:CHEBI:146163; CC Evidence={ECO:0000269|PubMed:11128635}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62997; CC Evidence={ECO:0000269|PubMed:11128635}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(11Z,14Z,17Z)-eicosatrienamide + H2O = (11Z,14Z,17Z)- CC eicosatrienoate + NH4(+); Xref=Rhea:RHEA:63000, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:28938, ChEBI:CHEBI:77223, ChEBI:CHEBI:146164; CC Evidence={ECO:0000269|PubMed:11128635}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63001; CC Evidence={ECO:0000269|PubMed:11128635}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(11Z,14Z)-eicosadienamide + H2O = (11Z,14Z)-eicosadienoate + CC NH4(+); Xref=Rhea:RHEA:63004, ChEBI:CHEBI:15377, ChEBI:CHEBI:28938, CC ChEBI:CHEBI:77220, ChEBI:CHEBI:146165; CC Evidence={ECO:0000269|PubMed:11128635}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63005; CC Evidence={ECO:0000269|PubMed:11128635}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(9Z,12Z)-octadecadienamide + H2O = (9Z,12Z)-octadecadienoate + CC NH4(+); Xref=Rhea:RHEA:63020, ChEBI:CHEBI:15377, ChEBI:CHEBI:28938, CC ChEBI:CHEBI:30245, ChEBI:CHEBI:82984; CC Evidence={ECO:0000269|PubMed:11128635}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63021; CC Evidence={ECO:0000269|PubMed:11128635}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + tetradecamide = NH4(+) + tetradecanoate; CC Xref=Rhea:RHEA:62992, ChEBI:CHEBI:15377, ChEBI:CHEBI:28938, CC ChEBI:CHEBI:30807, ChEBI:CHEBI:137125; CC Evidence={ECO:0000269|PubMed:9122178}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62993; CC Evidence={ECO:0000269|PubMed:9122178}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-(9Z-octadecenoyl) ethanolamine = (9Z)-octadecenoate + CC ethanolamine; Xref=Rhea:RHEA:45060, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:30823, ChEBI:CHEBI:57603, ChEBI:CHEBI:71466; CC Evidence={ECO:0000269|PubMed:15533037}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45061; CC Evidence={ECO:0000269|PubMed:15533037}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-(9Z-octadecenoyl)-taurine = (9Z)-octadecenoate + CC taurine; Xref=Rhea:RHEA:63148, ChEBI:CHEBI:15377, ChEBI:CHEBI:30823, CC ChEBI:CHEBI:146191, ChEBI:CHEBI:507393; CC Evidence={ECO:0000269|PubMed:15533037}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63149; CC Evidence={ECO:0000269|PubMed:15533037}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-O-methyl-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H2O = CC (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + methanol; CC Xref=Rhea:RHEA:63052, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:17790, ChEBI:CHEBI:32395, ChEBI:CHEBI:78033; CC Evidence={ECO:0000269|PubMed:9299394}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63053; CC Evidence={ECO:0000269|PubMed:9299394}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(11Z)-eicosenamide + H2O = (11Z)-eicosenoate + NH4(+); CC Xref=Rhea:RHEA:63120, ChEBI:CHEBI:15377, ChEBI:CHEBI:28938, CC ChEBI:CHEBI:32426, ChEBI:CHEBI:146167; CC Evidence={ECO:0000269|PubMed:11128635}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63121; CC Evidence={ECO:0000269|PubMed:11128635}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-(9Z-hexadecenoyl) ethanolamine = (9Z)-hexadecenoate + CC ethanolamine; Xref=Rhea:RHEA:35563, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:32372, ChEBI:CHEBI:57603, ChEBI:CHEBI:71465; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35564; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-octadecanoyl ethanolamine = ethanolamine + CC octadecanoate; Xref=Rhea:RHEA:63124, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:25629, ChEBI:CHEBI:57603, ChEBI:CHEBI:85299; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63125; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-docosanoyl-ethanolamine = docosanoate + ethanolamine; CC Xref=Rhea:RHEA:63128, ChEBI:CHEBI:15377, ChEBI:CHEBI:23858, CC ChEBI:CHEBI:57603, ChEBI:CHEBI:146186; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63129; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-tetracosanoyl-taurine = taurine + tetracosanoate; CC Xref=Rhea:RHEA:63140, ChEBI:CHEBI:15377, ChEBI:CHEBI:31014, CC ChEBI:CHEBI:132049, ChEBI:CHEBI:507393; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63141; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-(15Z-tetracosenoyl)-ethanolamine = (15Z)- CC tetracosenoate + ethanolamine; Xref=Rhea:RHEA:63144, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:32392, ChEBI:CHEBI:57603, CC ChEBI:CHEBI:146187; Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63145; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-docosanoyl-taurine = docosanoate + taurine; CC Xref=Rhea:RHEA:63156, ChEBI:CHEBI:15377, ChEBI:CHEBI:23858, CC ChEBI:CHEBI:146196, ChEBI:CHEBI:507393; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63157; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-(15Z-tetracosenoyl)-taurine = (15Z)-tetracosenoate + CC taurine; Xref=Rhea:RHEA:63160, ChEBI:CHEBI:15377, ChEBI:CHEBI:32392, CC ChEBI:CHEBI:146198, ChEBI:CHEBI:507393; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63161; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-tricosanoyl-taurine = taurine + tricosanoate; CC Xref=Rhea:RHEA:63164, ChEBI:CHEBI:15377, ChEBI:CHEBI:79007, CC ChEBI:CHEBI:146197, ChEBI:CHEBI:507393; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63165; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(9Z)-octadecenoate + glycine = H2O + N-(9Z- CC octadecenoyl)glycine; Xref=Rhea:RHEA:51316, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:30823, ChEBI:CHEBI:57305, ChEBI:CHEBI:133992; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:51318; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-glycine = CC (5Z,8Z,11Z,14Z)-eicosatetraenoate + glycine; Xref=Rhea:RHEA:64108, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:32395, ChEBI:CHEBI:57305, CC ChEBI:CHEBI:59002; Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64109; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- CATALYTIC ACTIVITY: CC Reaction=H2O + N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-L-serine = CC (5Z,8Z,11Z,14Z)-eicosatetraenoate + L-serine; Xref=Rhea:RHEA:64116, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:32395, ChEBI:CHEBI:33384, CC ChEBI:CHEBI:149697; Evidence={ECO:0000250|UniProtKB:O08914}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64117; CC Evidence={ECO:0000250|UniProtKB:O08914}; CC -!- ACTIVITY REGULATION: inhibited by trifluoromethyl ketone. CC {ECO:0000269|PubMed:9122178}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=23 uM for oleamide ((9Z)-octadecenamide) CC {ECO:0000269|PubMed:9790682}; CC KM=100 uM for arachidonamide ((5Z,8Z,11Z,14Z)-eicosatetraenamide) CC {ECO:0000269|PubMed:9299394}; CC KM=45 uM for methyl arachidonate CC (1-O-methyl-(5Z,8Z,11Z,14Z)-eicosatetraenoate) CC {ECO:0000269|PubMed:9299394}; CC KM=18 uM for anandamide CC (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine) CC {ECO:0000269|PubMed:9299394}; CC KM=34 uM for anandamide CC (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine) CC {ECO:0000269|PubMed:17649977}; CC KM=89 uM for 2-arachidonoylglycerol CC (2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycerol) CC {ECO:0000269|PubMed:17649977}; CC Vmax=0.11 umol/min/mg enzyme for the hydrolysis of anandamide CC (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine) CC {ECO:0000269|PubMed:10526230}; CC Note=kcat is 7.1 sec(-1) with oleamide ((9Z)-octadecenamide) CC (PubMed:9790682). kcat is 28 min(-1) with 2-arachidonoylglycerol CC (2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycerol) (PubMed:17649977). kcat CC is 16 min(-1) with anandamide CC (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine) (PubMed:17649977). CC {ECO:0000269|PubMed:17649977, ECO:0000269|PubMed:9790682}; CC pH dependence: CC Optimum pH is 9.5. {ECO:0000269|PubMed:9790682}; CC -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:12459591, CC ECO:0000269|PubMed:18753625}. CC -!- INTERACTION: CC P97612; P97612: Faah; NbExp=2; IntAct=EBI-15726093, EBI-15726093; CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:9122178, ECO:0000269|PubMed:9790682}; Single-pass CC membrane protein {ECO:0000269|PubMed:9122178}. Golgi apparatus membrane CC {ECO:0000269|PubMed:9122178, ECO:0000269|PubMed:9790682}; Single-pass CC membrane protein {ECO:0000269|PubMed:9122178}. Note=Seems to be CC associated with the endoplasmic reticulum and/or Golgi apparatus. CC -!- TISSUE SPECIFICITY: Found in neuronal cells throughout the CNS. CC Expressed in liver and brain, and to a lesser extent in spleen, lung, CC kidney and testes. {ECO:0000269|PubMed:9452020}. CC -!- DEVELOPMENTAL STAGE: In the CNS it accumulates progressively between CC embryonic day 14 and postnatal day 10, remains high until postnatal day CC 30, then decreases into adulthood. CC -!- SIMILARITY: Belongs to the amidase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U72497; AAB26961.1; -; mRNA. DR EMBL; BC091148; AAH91148.1; -; mRNA. DR RefSeq; NP_077046.1; NM_024132.3. DR RefSeq; XP_003750049.1; XM_003750001.4. DR RefSeq; XP_008774266.1; XM_008776044.2. DR PDB; 1MT5; X-ray; 2.80 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=37-573. DR PDB; 2VYA; X-ray; 2.75 A; A/B=32-579. DR PDB; 2WAP; X-ray; 2.80 A; A/B=31-573. DR PDB; 2WJ1; X-ray; 1.84 A; A/B=30-579. DR PDB; 2WJ2; X-ray; 2.55 A; A/B=30-579. DR PDB; 3K7F; X-ray; 1.95 A; A/B=30-579. DR PDB; 3K83; X-ray; 2.25 A; A/B=30-579. DR PDB; 3K84; X-ray; 2.25 A; A/B=30-579. DR PDB; 3LJ6; X-ray; 2.42 A; A/B=30-579. DR PDB; 3LJ7; X-ray; 2.30 A; A/B=30-579. DR PDB; 3OJ8; X-ray; 1.90 A; A/B=30-579. DR PDB; 3PPM; X-ray; 1.78 A; A/B=30-579. DR PDB; 3PR0; X-ray; 2.20 A; A/B=30-579. DR PDB; 3QJ8; X-ray; 2.90 A; A/B=32-579. DR PDB; 3QJ9; X-ray; 2.30 A; A/B=32-579. DR PDB; 3QK5; X-ray; 2.20 A; A/B=32-579. DR PDB; 3QKV; X-ray; 3.10 A; A/B=32-579. DR PDB; 4DO3; X-ray; 2.25 A; A/B=32-575. DR PDB; 4HBP; X-ray; 2.91 A; A/B=30-579. DR PDB; 4J5P; X-ray; 2.30 A; A/B=30-579. DR PDB; 6MRG; X-ray; 2.77 A; A/B/C/D=32-579. DR PDBsum; 1MT5; -. DR PDBsum; 2VYA; -. DR PDBsum; 2WAP; -. DR PDBsum; 2WJ1; -. DR PDBsum; 2WJ2; -. DR PDBsum; 3K7F; -. DR PDBsum; 3K83; -. DR PDBsum; 3K84; -. DR PDBsum; 3LJ6; -. DR PDBsum; 3LJ7; -. DR PDBsum; 3OJ8; -. DR PDBsum; 3PPM; -. DR PDBsum; 3PR0; -. DR PDBsum; 3QJ8; -. DR PDBsum; 3QJ9; -. DR PDBsum; 3QK5; -. DR PDBsum; 3QKV; -. DR PDBsum; 4DO3; -. DR PDBsum; 4HBP; -. DR PDBsum; 4J5P; -. DR PDBsum; 6MRG; -. DR AlphaFoldDB; P97612; -. DR SMR; P97612; -. DR DIP; DIP-46284N; -. DR IntAct; P97612; 1. DR STRING; 10116.ENSRNOP00000015667; -. DR BindingDB; P97612; -. DR ChEMBL; CHEMBL3229; -. DR DrugCentral; P97612; -. DR GuidetoPHARMACOLOGY; 1400; -. DR SwissLipids; SLP:000001428; -. DR iPTMnet; P97612; -. DR PhosphoSitePlus; P97612; -. DR jPOST; P97612; -. DR PaxDb; 10116-ENSRNOP00000015667; -. DR Ensembl; ENSRNOT00000015667.8; ENSRNOP00000015667.6; ENSRNOG00000045949.3. DR Ensembl; ENSRNOT00055054982; ENSRNOP00055045429; ENSRNOG00055031772. DR Ensembl; ENSRNOT00060047749; ENSRNOP00060039713; ENSRNOG00060027493. DR Ensembl; ENSRNOT00065026704; ENSRNOP00065020953; ENSRNOG00065016061. DR UCSC; RGD:61808; rat. DR AGR; RGD:61808; -. DR RGD; 61808; Faah. DR eggNOG; KOG1212; Eukaryota. DR GeneTree; ENSGT00940000161237; -. DR HOGENOM; CLU_009600_9_3_1; -. DR InParanoid; P97612; -. DR OMA; GMQPWKY; -. DR OrthoDB; 731186at2759; -. DR BRENDA; 3.5.1.4; 5301. DR BRENDA; 3.5.1.99; 5301. DR Reactome; R-RNO-2142753; Arachidonic acid metabolism. DR SABIO-RK; P97612; -. DR EvolutionaryTrace; P97612; -. DR PRO; PR:P97612; -. DR Proteomes; UP000002494; Chromosome 5. DR Bgee; ENSRNOG00000011019; Expressed in jejunum and 13 other cell types or tissues. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0031090; C:organelle membrane; IDA:UniProtKB. DR GO; GO:0047372; F:acylglycerol lipase activity; IDA:UniProtKB. DR GO; GO:0004040; F:amidase activity; IDA:RGD. DR GO; GO:0017064; F:fatty acid amide hydrolase activity; IDA:UniProtKB. DR GO; GO:0016788; F:hydrolase activity, acting on ester bonds; IDA:RGD. DR GO; GO:0042802; F:identical protein binding; IMP:RGD. DR GO; GO:0008289; F:lipid binding; IDA:RGD. DR GO; GO:0005543; F:phospholipid binding; IMP:RGD. DR GO; GO:0009062; P:fatty acid catabolic process; IDA:UniProtKB. DR GO; GO:0006631; P:fatty acid metabolic process; IMP:RGD. DR GO; GO:0052651; P:monoacylglycerol catabolic process; IDA:UniProtKB. DR GO; GO:0045907; P:positive regulation of vasoconstriction; IMP:RGD. DR Gene3D; 3.90.1300.10; Amidase signature (AS) domain; 1. DR InterPro; IPR020556; Amidase_CS. DR InterPro; IPR023631; Amidase_dom. DR InterPro; IPR036928; AS_sf. DR PANTHER; PTHR45847; FATTY ACID AMIDE HYDROLASE; 1. DR PANTHER; PTHR45847:SF3; FATTY-ACID AMIDE HYDROLASE 1; 1. DR Pfam; PF01425; Amidase; 1. DR PIRSF; PIRSF001221; Amidase_fungi; 1. DR SUPFAM; SSF75304; Amidase signature (AS) enzymes; 1. DR PROSITE; PS00571; AMIDASES; 1. DR Genevisible; P97612; RN. PE 1: Evidence at protein level; KW 3D-structure; Direct protein sequencing; Endoplasmic reticulum; KW Golgi apparatus; Hydrolase; Lipid degradation; Lipid metabolism; Membrane; KW Phosphoprotein; Reference proteome; Transmembrane; Transmembrane helix. FT CHAIN 1..579 FT /note="Fatty-acid amide hydrolase 1" FT /id="PRO_0000105267" FT TRANSMEM 9..29 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 30..403 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT INTRAMEM 404..433 FT /evidence="ECO:0000305" FT TOPO_DOM 434..579 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT ACT_SITE 142 FT /note="Charge relay system" FT ACT_SITE 217 FT /note="Charge relay system" FT ACT_SITE 241 FT /note="Acyl-ester intermediate" FT BINDING 191 FT /ligand="substrate" FT BINDING 217 FT /ligand="substrate" FT BINDING 238..241 FT /ligand="substrate" FT MOD_RES 241 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O00519" FT MUTAGEN 142 FT /note="K->A: Lowers activity 40000-fold. Lowers activity FT 70000-fold; when associated with A-217." FT /evidence="ECO:0000269|PubMed:12734197" FT MUTAGEN 217 FT /note="S->A: Lowers activity 3000-fold. Lowers activity FT 70000-fold; when associated with A-142." FT /evidence="ECO:0000269|PubMed:12734197" FT HELIX 35..65 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 71..76 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 79..87 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 89..91 FT /evidence="ECO:0007829|PDB:3OJ8" FT HELIX 93..111 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 114..117 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 121..127 FT /evidence="ECO:0007829|PDB:3PPM" FT TURN 133..136 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 138..142 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 164..166 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 169..176 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 180..185 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 189..191 FT /evidence="ECO:0007829|PDB:3QK5" FT STRAND 193..195 FT /evidence="ECO:0007829|PDB:3PPM" FT TURN 199..201 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 216..218 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 219..226 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 231..240 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 243..249 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 252..255 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 258..260 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 279..286 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 287..297 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 300..305 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 316..319 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 326..329 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 334..336 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 340..355 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 359..362 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 368..373 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 375..380 FT /evidence="ECO:0007829|PDB:3PPM" FT TURN 382..385 FT /evidence="ECO:0007829|PDB:1MT5" FT HELIX 386..389 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 390..392 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 399..401 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 404..408 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 412..422 FT /evidence="ECO:0007829|PDB:3PPM" FT TURN 423..425 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 427..435 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 436..438 FT /evidence="ECO:0007829|PDB:3LJ7" FT HELIX 441..464 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 468..473 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 484..486 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 488..491 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 492..499 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 504..511 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 514..520 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 530..538 FT /evidence="ECO:0007829|PDB:3PPM" FT STRAND 546..552 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 558..572 FT /evidence="ECO:0007829|PDB:3PPM" FT HELIX 574..576 FT /evidence="ECO:0007829|PDB:3PR0" SQ SEQUENCE 579 AA; 63357 MW; 606491C0B033E1AA CRC64; MVLSEVWTTL SGVSGVCLAC SLLSAAVVLR WTGRQKARGA ATRARQKQRA SLETMDKAVQ RFRLQNPDLD SEALLTLPLL QLVQKLQSGE LSPEAVFFTY LGKAWEVNKG TNCVTSYLTD CETQLSQAPR QGLLYGVPVS LKECFSYKGH DSTLGLSLNE GMPSESDCVV VQVLKLQGAV PFVHTNVPQS MLSFDCSNPL FGQTMNPWKS SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSAFCG ICGLKPTGNR LSKSGLKGCV YGQTAVQLSL GPMARDVESL ALCLKALLCE HLFTLDPTVP PLPFREEVYR SSRPLRVGYY ETDNYTMPSP AMRRALIETK QRLEAAGHTL IPFLPNNIPY ALEVLSAGGL FSDGGRSFLQ NFKGDFVDPC LGDLILILRL PSWFKRLLSL LLKPLFPRLA AFLNSMRPRS AEKLWKLQHE IEMYRQSVIA QWKAMNLDVL LTPMLGPALD LNTPGRATGA ISYTVLYNCL DFPAGVVPVT TVTAEDDAQM ELYKGYFGDI WDIILKKAMK NSVGLPVAVQ CVALPWQEEL CLRFMREVEQ LMTPQKQPS //